Arformoterol Tartrate Inhalation Solution 15 mcg*/2 mL For Oral Inhalation Only Rx Only Manufactu...
FDA Drug Recall #D-0827-2021 — Class II — August 27, 2021
Recall Summary
| Recall Number | D-0827-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 27, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Glenmark Pharmaceuticals Inc., USA |
| Location | Mahwah, NJ |
| Product Type | Drugs |
| Quantity | a) 5362 inhalers; b) 5593 inhalers |
Product Description
Arformoterol Tartrate Inhalation Solution 15 mcg*/2 mL For Oral Inhalation Only Rx Only Manufactured by: Glenmark Pharmaceuticals Inc., USA Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 a) 60x2 mL Sterile Unit-Dose Vials NDC 68462-833-65; b) 30x2 mL Sterile Unit-Dose Vials NDC 68462-833-35
Reason for Recall
Lack of Assurance of Sterility
Distribution Pattern
Nationwide.
Lot / Code Information
Lots: a) 30210041 Exp. 03/31/2023; 30210045 Exp. 04/30/2023; 30210046 Exp. 04/30/2023; 30210050 Exp. 03/31/2023; 30210051 Exp. 04/30/2023; 30210058 Exp. 04/30/2023; b) 30210042 Exp. 03/31/2023; 30210047 Exp. 04/30/2023; 30210048 Exp. 04/30/2023; 30210052 Exp. 04/30/2023; 30210053 Exp. 04/30/2023; 30210054 Exp. 04/30/2023; 30210059 Exp. 04/30/2023; 30210060 Exp. 04/30/2023; 30210061 Exp. 04/30/2023; 30210062 Exp. 04/30/2023; 30210063 Exp. 04/30/2023; 30210064 Exp. 05/31/2023
Other Recalls from Glenmark Pharmaceuticals Inc., USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0246-2026 | Class II | Ondansetron Orally Disintegrating Tablets, USP,... | Dec 30, 2025 |
| D-0199-2026 | Class III | Bisoprolol Fumarate and Hydrochlorothiazide Tab... | Nov 21, 2025 |
| D-0222-2026 | Class III | Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... | Nov 18, 2025 |
| D-0662-2025 | Class II | Azelaic Acid Gel, 15%, 50 grams, For Topical Us... | Sep 17, 2025 |
| D-0021-2026 | Class II | Viorele, Desogestrel and Ethinyl Estradiol, USP... | Sep 3, 2025 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.